Globe Life falls over 4% on earnings miss, lowered guidance
Globe Life Inc. (GL) reported Q3 adjusted EPS of $4.84, missing estimates by $0.07, but revenue of $1.6B exceeded expectations. Shares fell 4.7% after hours. The company lowered 2026 EPS guidance to $15.35-$15.65 due to issues at its United American division. 2027 EPS guidance was set at $16.10-$17.10. GL repurchased 1.1M shares in Q3 and increased its share buyback guidance.
How this was made
The 30-second read
Why it matters
The combination of an EPS miss and a lowered 2026 earnings range is a direct repricing catalyst for GL, with the stated driver being claims severity and CMS-related processing delays that created excess Medicare Supplement claims during the quarter.
Market read
GL’s after-hours drop is tied to fresh guidance and operational explanations, making it a near-term catalyst for positioning and risk management in insurer names.
What to watch
The article notes higher premium revenue and increased buyback guidance; traders may underweight the potential offset from repurchases and premium growth when focusing only on the EPS miss and guidance range.
Background
Globe Life is a US life and health insurer with earnings sensitivity to claims experience and Medicare Supplement administration through its agency operations.
Ticker impact
Globe Life reported Q3 adjusted EPS of $4.84 vs $4.91 estimates and lowered full-year 2026 guidance to $15.35-$15.65 due to issues at United American General Agency.
Likely further pressure as the market reprices 2026 earnings power and questions whether the UAG agency problems are temporary.
The article cites both a miss (EPS) and a specific guidance reduction, with management attributing it to identifiable operational/claims-processing factors rather than a broad business deterioration.
Market effects
Reinforces that Medicare Supplement and agency-channel claims administration execution can drive earnings volatility for insurers.
Limited, company-specific move within US life and health insurance equities.
Low, no cross-market policy or macro linkage beyond general risk sentiment.
Counterpoint
Management frames the guidance cut as driven by two items at the United American General Agency division, not a fundamental change in core business, which could support a rebound if investors view it as non-recurring.
Key entities
- companyGlobe Life Inc.
Subject of the article, reporting Q3 results, lowering 2026 guidance, and updating buyback guidance.
- business_unitUnited American General Agency division
Division cited as the source of the guidance revision due to high-severity claims and CMS claims processing delays.
- regulatorCenters for Medicare and Medicaid Services (CMS)
Referenced as the source of a claims processing delay that contributed to excess Medicare Supplement claims.
